Details for Patent: 6,713,086

Summary for Patent: 6,713,086

Patent landscape, scope, and claims:

Title:	Controlled release formulation of divalproex sodium
Abstract:	A new oral polymeric controlled release formulation suitable for the once-a-day administration of valproate compounds, such as divalproex sodium, has been discovered. This formulation exhibits significant advantages over the sustained release valproate formulations of the prior art. This formulation minimizes the variation between peak and trough plasma levels of valproate over a 24 hour dosing period. This formulation follows a zero-order release pattern thus producing essentially flat plasma levels of valproate, once steady-state levels have been achieved. This results in a significantly lower incidence of side effects for patients consuming such a formulation.
Inventor(s):	Qiu; Yihong (Gumee, IL), Bollinger; J. Daniel (Libertyville, IL), Cheskin; Howard S. (Glencoe, IL), Dutta; Sandeep (Waukegan, IL), Engh; Kevin R. (Kenosha, IL), Poska; Richard P. (Mundelein, IL)
Assignee:	Abbott Laboratories (Abbott Park, IL)
Application Number:	10/215,142
Patent Claim Types: see list of patent claims	Formulation; Compound; Dosage form; Delivery; Device; Use;

Drugs Protected by US Patent 6,713,086

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 6,713,086

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	021443
Austria	254907
Austria	275398